CBA Commercial Assets Series 2005-1 Class M-2 Rating Lowered To 'D (sf)' Dec 11

  • ID: 2030120
  • December 2011
  • Standard & Poors

OVERVIEW We lowered our rating to 'D (sf)' on the class M-2 CMBS certificate from CBA Commercial Assets' series 2005-1, a U.S. CMBS transaction, reflecting a $1,234,968 principal loss. NEW YORK (Standard & Poor's) Dec. 9, 2011--Standard & Poor's Ratings Services today lowered its rating to 'D (sf)' on the class M-2 commercial mortgage pass-through certificates from CBA Commercial Assets 2005-1, a U.S. commercial mortgage backed securities (CMBS) transaction. The downgrade of the class M-2 certificate to 'D (sf)' reflects a $1,234,968 principal loss, 21.9% to the outstanding principal balance. The current outstanding principal balance for class M-2 as of the Nov. 25, 2011, remittance report is $4,405,031. In addition, the class M-3 certificate also experienced a principal loss. The...

Companies mentioned in this report are: CBA Commercial Assets 2005-1
Action: Downgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown

CBA Commercial Assets 2005-1

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.